Grant: Op. Gr: NI grants in MRC&Y Health - M, R and Childhood and Adolescent Cancers
University of Alberta
$74,930.00
Mitigating cisplatin-induced ototoxicity in childhood cancer treatment through applied pharmacogenomics
FY 2017-18
Summary
Advances in the treatment of childhood cancer have successfully increased the 5-year survival rate to almost 80%. While this is a dramatic improvement over the 1960s survival rate, it comes at the cost of causing poor long-term health outcomes for the majority of children treated with chemotherapy. Studies that follow childhood cancer survivors into adulthood clearly show that children receiving chemotherapy suffer serious health complications that include major organ and sensory toxicities. These toxicities, known as adverse drug reactions (ADRs), can also occur soon after the completion of chemotherapy, or even during treatment resulting in the withdrawal of life-saving cancer drugs. For example, cisplatin is the chemotherapy of choice for treating solid tumours in children including brain, liver, bone and germ cell cancers. Unfortunately over half of treated children will permanently lose their hearing after receiving cisplatin, which severely impairs a child's ability to develop language skills, social skills and self-confidence. We now know that genetic differences between children can influence whether hearing loss, or other ADRs will develop from chemotherapy treatment. Pharmacogenomics is the study of how genetic variation influences drug response and this understanding can open the door to developing tools to predict and prevent the occurrence of ADRs. We have now completed the first stage of a comprehensive pharmacogenomic study in Canadian patients that has identified a new pathway involved in cisplatin-induced hearing loss. This project will capitalize on this discovery and explore its application towards developing predictive biomarkers and preventative treatments to reduce the occurrence of cisplatin-induced hearing loss in childhood cancer patients.
Department
Program
Op. Gr: NI grants in MRC&Y Health - M, R and Childhood and Adolescent Cancers
Recipient
Location
Alberta, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
367658
Name
Bhavsar Amit P
Region
Alberta
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Human Development, Child and Youth Health
Theme2
Biomedical
Prcname2
Operating Grant: New Investigator Grants in Maternal, Reproductive, Child & Youth Health
Projecttitle
Mitigating cisplatin-induced ototoxicity in childhood cancer treatment through applied pharmacogenomics
Programtype2
Operating Grants
Orgnameinp2
University of Alberta
Cihramount2
$74,930
Cihrequipment2
$0
Programname2
Op. Gr: NI grants in MRC&Y Health - M, R and Childhood and Adolescent Cancers
Keyworddelim
Adverse Drug Reactions; Cisplatin-Induced Ototoxicity; Gwas; Pediatric Oncology; Pharmacogenomics; Predictive Biomarker; Prophylaxis
Abstract
Advances in the treatment of childhood cancer have successfully increased the 5-year survival rate to almost 80%. While this is a dramatic improvement over the 1960s survival rate, it comes at the cost of causing poor long-term health outcomes for the majority of children treated with chemotherapy. Studies that follow childhood cancer survivors into adulthood clearly show that children receiving chemotherapy suffer serious health complications that include major organ and sensory toxicities. These toxicities, known as adverse drug reactions (ADRs), can also occur soon after the completion of chemotherapy, or even during treatment resulting in the withdrawal of life-saving cancer drugs. For example, cisplatin is the chemotherapy of choice for treating solid tumours in children including brain, liver, bone and germ cell cancers. Unfortunately over half of treated children will permanently lose their hearing after receiving cisplatin, which severely impairs a child's ability to develop language skills, social skills and self-confidence. We now know that genetic differences between children can influence whether hearing loss, or other ADRs will develop from chemotherapy treatment. Pharmacogenomics is the study of how genetic variation influences drug response and this understanding can open the door to developing tools to predict and prevent the occurrence of ADRs. We have now completed the first stage of a comprehensive pharmacogenomic study in Canadian patients that has identified a new pathway involved in cisplatin-induced hearing loss. This project will capitalize on this discovery and explore its application towards developing predictive biomarkers and preventative treatments to reduce the occurrence of cisplatin-induced hearing loss in childhood cancer patients.
Competitiondate
201705
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Bhavsar, Amit P
Approvedterm
3 ans 0 mois
Cihrcontribution2
Inst of Cancer Research~ $74,930~ $0~